Maintenance rituximab after autologous stem cell transplant for high-risk B-cell lymphoma induces prolonged and severe hypogammaglobulinemia [4]

Bone Marrow Transplantation

Volumn 35, Issue 2, 2005, Pages 207-208

  Lim, S H ^a   Zhang, Y ^a   Wang, Z ^a   Esler, W V ^a   Beggs, D ^a   Pruitt, B ^a   Hancock, P ^a   Townsend, M ^a  

^a TEXAS TECH UNIVERSITY HEALTH SCIENCES CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD20 ANTIGEN; CD34 ANTIGEN; CISPLATIN; CYCLOPHOSPHAMIDE; CYTARABINE; DOXORUBICIN; IMMUNOGLOBULIN; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; MELPHALAN; PREDNISOLONE; RITUXIMAB; VANCOMYCIN; VINCRISTINE;

ADULT; AGED; AUTOLOGOUS STEM CELL TRANSPLANTATION; B CELL LYMPHOMA; CANCER COMBINATION CHEMOTHERAPY; CANCER REGRESSION; CHRONIC DIARRHEA; CLINICAL ARTICLE; CLINICAL OBSERVATION; DIARRHEA; DISEASE SEVERITY; DRUG EFFECT; DRUG SAFETY; FEMALE; FOLLOW UP; HIGH RISK PATIENT; HUMAN; HUMAN CELL; HYPOGAMMAGLOBULINEMIA; IMMUNOGLOBULIN BLOOD LEVEL; IMMUNOGLOBULIN DEFICIENCY; INFECTION; INFECTION RISK; LARGE CELL LYMPHOMA; LETTER; LYMPHOCYTE DEPLETION; LYMPHOMA; MAINTENANCE THERAPY; MALE; MANTLE CELL LYMPHOMA; MYELOMA; PRIORITY JOURNAL; RISK ASSESSMENT;

AGAMMAGLOBULINEMIA; ANTIBODIES, MONOCLONAL; FEMALE; HUMANS; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; LYMPHOMA, B-CELL; MALE; TRANSPLANTATION, AUTOLOGOUS;

EID: 13244249651     PISSN: 02683369     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bmt.1704742     Document Type: Letter

References (5)

1. Lim SH, Zhang Y, Wang Z et al. Rituximab administration following autologous stem cell transplant for multiple myeloma is associated with severe IgM deficiency. Blood 2004; 103: 1971-1972.
2. Ashihara E, Shimazaki C, Yamagata N et al. Reconstitution of lymphocyte subsets after peripheral blood stem cell transplantation: two-color flow cytometric analysis. Bone Marrow Transplant 1994; 13: 377-381.
3. Koehne G, Zeller W, Stockschlaeder M, Zander AR. Phenotype of lymphocyte subsets after autologous peripheral blood stem cell transplantation. Bone Marrow Transplant 1997; 19: 149-156.
4. Talmadge JE, Reed E, Ino K et al. Rapid immunologic reconstitution following blood stem cells as compared to bone marrow. Bone Marrow Transplant 1997; 19: 161-172.
5. Horwitz SM, Negrin RS, Blume KG et al. Rituximab as adjuvant to high-dose therapy and autologous hematopoietic cell transplantation for aggressive non-Hodgkin's lymphoma. Blood 2004; 103: 777-783.